Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.10 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (myonuclei) | 0.10 |
| chemistry Open Targets | compounds already reach it: amlodipine benzoate, manidipine 6300, diltiazem +38 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 362 | 0.91 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 2533
Sealed predictions
- CACNA1S in dopamine neurons, braak-0.67 (p 0.050) → -0.61 (p 0.084)receipt 2540
Swarm cases
receipt 2540: CACNA1S in dopamine neurons, braak
- power
- full sample -0.51 (p 0.031, n 18), 95% CI -0.79 to -0.06. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.54 (p 0.019, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.75 (p 3.3e-4, n 18). not the mix.
- skeptic
- leave-one-out range -0.62 to -0.45, sign flips 0; without severely affected donors -0.51 (p 0.031, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CACNA1S in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts